Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scandinavian Clinical Nutrition, through its US subsidiary SCN USA, has signed an agreement with the company's US partner Inverness Medical Innovations regarding US mass market distribution of the cold product Coldizin.
Subscribe to our email newsletter
The product will be launched immediately in more than 20,000 retail outlets under the trademark Coldizin24, at a very low risk for Scandinavian Clinical Nutrition (SCN), and with potential to reach a total of 60,000 stores.
The partnership provides Inverness Medical a right of first refusal for products and technologies licensed to Scandinavian Clinical Nutrition developed by Karolinska Institutet, the Swedish institution that awards the Nobel Prize in physiology or medicine. To maintain exclusivity, Inverness has to sell at least 1.2 million units during the first year.
SCN has formed a 10-year, $10 million research agreement with Karolinska Institutet through a network of excellence, which will serve to benefit Inverness Medical, which also maintains a strong focus on the research, development and distribution of new products.
Thomas Christensen, CEO of SCN, said: “By launching Coldizin24 with a prominent partner such as Inverness Medical, we will build our own brand on the US market for cold products, which has an annual turnover of $5.3 billion. We estimate the value of the agreement to at least SEK30 to 40 million in net sales.”